MX366180B - Nuevos agentes de union a ha. - Google Patents

Nuevos agentes de union a ha.

Info

Publication number
MX366180B
MX366180B MX2014013668A MX2014013668A MX366180B MX 366180 B MX366180 B MX 366180B MX 2014013668 A MX2014013668 A MX 2014013668A MX 2014013668 A MX2014013668 A MX 2014013668A MX 366180 B MX366180 B MX 366180B
Authority
MX
Mexico
Prior art keywords
union
new agents
antigen
antibodies
bind
Prior art date
Application number
MX2014013668A
Other languages
English (en)
Other versions
MX2014013668A (es
Inventor
Shriver Zachary
Viswanathan Karthik
Subramanian Vidya
Raguram Sasisekharan
Original Assignee
Visterra Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49548781&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX366180(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Visterra Inc filed Critical Visterra Inc
Publication of MX2014013668A publication Critical patent/MX2014013668A/es
Publication of MX366180B publication Critical patent/MX366180B/es

Links

Classifications

    • C07K16/108—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)

Abstract

La presente invención se refiere a nuevos agentes peptídicos, por ejemplo, anticuerpos y fragmentos de unión a antígeno de los mismos, que se unen a la proteína hemaglutinina de virus de influenza, y métodos de su uso.
MX2014013668A 2012-05-10 2013-05-10 Nuevos agentes de union a ha. MX366180B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261645554P 2012-05-10 2012-05-10
US201261716447P 2012-10-19 2012-10-19
US13/830,367 US9969794B2 (en) 2012-05-10 2013-03-14 HA binding agents
PCT/US2013/040534 WO2013170139A1 (en) 2012-05-10 2013-05-10 Novel ha binding agents

Publications (2)

Publication Number Publication Date
MX2014013668A MX2014013668A (es) 2015-04-08
MX366180B true MX366180B (es) 2019-07-01

Family

ID=49548781

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014013668A MX366180B (es) 2012-05-10 2013-05-10 Nuevos agentes de union a ha.
MX2019007921A MX2019007921A (es) 2012-05-10 2014-11-10 Nuevos agentes de union a ha.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019007921A MX2019007921A (es) 2012-05-10 2014-11-10 Nuevos agentes de union a ha.

Country Status (13)

Country Link
US (5) US9969794B2 (es)
EP (2) EP3689377A1 (es)
JP (2) JP6363066B2 (es)
KR (2) KR102194936B1 (es)
CN (2) CN104602709B (es)
AU (3) AU2013259371B2 (es)
CA (1) CA2872308C (es)
CL (1) CL2014003051A1 (es)
ES (1) ES2785306T3 (es)
IL (1) IL235585B (es)
MX (2) MX366180B (es)
SG (2) SG10201605669WA (es)
WO (1) WO2013170139A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
US9624272B2 (en) 2013-03-14 2017-04-18 University Of Washington Through Its Center For Commercialization Polypeptides for treating and/or limiting influenza infection
AU2014236508A1 (en) 2013-03-14 2015-09-17 Contrafect Corporation Composition and methods based on neutralizing antibodies delivered intranasally for enhanced therapeutic efficacy
TWI701258B (zh) 2014-12-19 2020-08-11 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
AU2016214304B2 (en) 2015-02-05 2021-11-11 Janssen Vaccines & Prevention B.V. Binding molecules directed against influenza hemagglutinin and uses thereof
EP3280730B1 (en) 2015-04-08 2024-01-03 Dana-Farber Cancer Institute, Inc. Humanized influenza monoclonal antibodies and methods of use thereof
WO2016180826A1 (en) * 2015-05-11 2016-11-17 Janssen Vaccines & Prevention B.V. Influenza virus neutralizing peptidomimetic compounds
WO2016192652A1 (zh) * 2015-06-03 2016-12-08 厦门大学 抗Flu B的广谱单克隆抗体及其用途
EP3374390A1 (en) * 2015-11-13 2018-09-19 Visterra, Inc. Compositions and methods for treating and preventing influenza
EP3402520A4 (en) 2016-01-14 2019-01-02 BPS Bioscience, Inc. Anti-pd-1 antibodies and uses thereof
JP7104629B2 (ja) * 2016-02-24 2022-07-21 ビステラ， インコーポレイテッド インフルエンザウイルスに対する抗体分子の製剤
JP6800591B2 (ja) * 2016-03-11 2020-12-16 国立大学法人 岡山大学 インフルエンザ治療剤
WO2017192589A1 (en) * 2016-05-02 2017-11-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to influenza ha and their use and identification
CA3088194A1 (en) 2018-01-26 2019-08-01 Regeneron Pharmaceuticals, Inc. Human antibodies to influenza hemagglutinin
GB201814959D0 (en) * 2018-09-14 2018-10-31 Secr Defence Methods for the preparation of a pharmaceutical-vesicle formulation and associated products and uses
GB2578163A (en) * 2018-10-19 2020-04-22 Univ Pretoria Plant produced avian influenza antigens and their uses in diagnostic assays and devices
AU2020248404A1 (en) 2019-03-25 2021-09-30 Visterra, Inc. Compositions and methods for treating and preventing influenza
KR20220113749A (ko) * 2019-12-11 2022-08-16 비스테라, 인크. 인플루엔자를 치료하고 예방하는 조성물 및 방법
EP4441091A4 (en) * 2021-11-30 2025-12-17 Sab Llc UNGULATE-DERIVED POLYCLONAL IMMUNE GLOBULIN SPECIFIC FOR INFLUENCE VAVIRUS AND USES THEREOF

Family Cites Families (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL23522C (es) 1927-03-23
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
FI83662C (fi) 1980-07-17 1991-08-12 Scripps Clinic Res Diagnostik antikropp och foerfarande foer dess framstaellning.
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4625015A (en) 1982-08-23 1986-11-25 Scripps Clinic & Research Foundation Broad spectrum influenza antisera
ZA836080B (en) 1982-08-23 1984-04-25 Scripps Clinic Res Broad spectrum influenza antisera
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
JP2518607B2 (ja) 1985-08-29 1996-07-24 雪印乳業株式会社 インフルエンザａ型ウイルスｈａ抗原に対するモノクロ―ナル抗体およびその作成方法
AU603659B2 (en) 1987-03-13 1990-11-22 Micro Vesicular Systems, Inc. Lipid vesicles formed of surfactants and steroids
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
EP0417191B1 (en) 1988-05-27 1993-03-10 Centocor, Inc. Formulation for antibody reagents
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US6337070B1 (en) 1993-04-29 2002-01-08 Takara Shuzo Co., Ltd. Polypeptides for use in generating anti-human influenza virus antibodies
US5589174A (en) 1992-09-17 1996-12-31 Takara Shuzo Co., Ltd. Anti-human influenza virus antibody
GB9320597D0 (en) 1993-10-06 1993-11-24 Proteus Molecular Design Improvements in and realting to vaccines
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
JP2996864B2 (ja) 1994-03-30 2000-01-11 寳酒造株式会社 抗体可変領域ｄｎａ
DE19643314A1 (de) 1996-10-21 1998-04-23 Boehringer Mannheim Gmbh Monoklonale Antikörper gegen das Epitop YPYDVPDYA, Verfahren zu deren Herstellung und Verwendung
FR2817869B1 (fr) 2000-12-07 2005-01-14 Technopharm Anticorps monoclonal humain dirige contre le virus influenza ou un fragment de celui-ci
EP2364996B1 (en) 2002-09-27 2016-11-09 Xencor Inc. Optimized FC variants and methods for their generation
CA2517074A1 (en) 2003-02-27 2004-09-10 Yeda Research And Development Co., Ltd. Nucleic acid molecules, polypeptides, antibodies and compositions containing same useful for treating and detecting influenza virus infection
CA2816222A1 (en) 2003-06-16 2005-03-03 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
SI1698640T2 (sl) 2003-10-01 2019-08-30 Kyowa Hakko Kirin Co., Ltd. Postopek za stabiliziranje protitelesa in stabiliziran pripravek protitelesa tipa raztopina
DK2261376T3 (da) 2003-11-04 2013-10-07 Univ Tulane Fremgangsmåde til hindring af virus:celle-fusion ved hæmning af funktionen af fusionsinitieringsregionen i RNA vira med klasse I membranfusogene indhyldningsproteiner
JP2008504002A (ja) 2003-11-12 2008-02-14 バイオジェン・アイデック・エムエイ・インコーポレイテッド 新生児Ｆｃレセプター（ＦｃＲｎ）結合ポリペプチド改変体、ダイマーＦｃ結合タンパク質、およびそれらに関連する方法
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
US20060024670A1 (en) 2004-05-18 2006-02-02 Luke Catherine J Influenza virus vaccine composition and methods of use
ES2525672T3 (es) 2004-05-25 2014-12-29 Medimmune, Llc Variantes de la hemaglutinina y la neuraminidasa de influenza
WO2006069331A2 (en) * 2004-12-22 2006-06-29 The Salk Institute For Biological Studies Compositions and methods for producing recombinant proteins
US7572620B2 (en) 2005-01-11 2009-08-11 Wisconsin Alumni Research Foundation H3 equine influenza A virus
WO2006104615A2 (en) 2005-02-24 2006-10-05 University Of Massachusetts Influenza nucleic acids, polypeptides, and uses thereof
WO2007074880A1 (ja) 2005-12-28 2007-07-05 Chugai Seiyaku Kabushiki Kaisha 抗体含有安定化製剤
JP2009524434A (ja) * 2006-01-26 2009-07-02 エイチエックス・ダイアグノスティックス・インコーポレイテッド トリインフルエンザウイルス亜型ｈ５ヘマグルチニンに結合するモノクローナル抗体およびそれらの使用
US8222204B2 (en) 2006-05-03 2012-07-17 The Administrators of the Tulane Educational Fund and Autoimmune Technologies, LLC Influenza inhibiting compositions and methods
AU2007249160B2 (en) 2006-05-15 2013-09-12 I2 Pharmaceuticals, Inc. Neutralizing antibodies to influenza viruses
WO2007149715A2 (en) 2006-06-16 2007-12-27 Dow Agrosciences Llc Novel dna sequences, vectors and proteins of avian influenza hemagglutinin
US20090081193A1 (en) 2006-08-14 2009-03-26 Massachusetts Institute Of Technology Hemagglutinin polypeptides, and reagents and methods relating thereto
CA2660128A1 (en) 2006-08-14 2008-02-21 Massachusetts Institute Of Technology Glycan data mining system
US20090269342A1 (en) 2006-08-14 2009-10-29 Massachusetts Institute Of Technology Hemagglutinin Polypeptides, and Reagents and Methods Relating Thereto
HRP20130163T1 (hr) 2006-09-07 2013-03-31 Crucell Holland B.V. Ljudske molekule za vezanje koje mogu neutralizirati virus influence h5n1 i njihova uporaba
WO2008033105A1 (en) 2006-09-13 2008-03-20 Dso National Laboratories Hemagglutinin antibody and uses thereof
JP4625485B2 (ja) 2006-09-29 2011-02-02 財団法人大阪産業振興機構 高病原性トリインフルエンザウイルスに対するモノクローナル抗体
TWI403518B (zh) 2007-01-23 2013-08-01 Academia Sinica 一種流感疫苗及其使用方法
US8124092B2 (en) 2007-03-13 2012-02-28 Institute For Research In Biomedicine Antibodies against H5N1 strains of influenza A virus
KR101540822B1 (ko) 2007-03-27 2015-07-30 씨 레인 바이오테크놀로지스, 엘엘씨 항체 대용물 경쇄 서열을 포함하는 구축물 및 라이브러리
WO2008140415A1 (en) 2007-05-11 2008-11-20 Temasek Life Sciences Laboratory Limited H5 subtype-specific binding proteins useful for h5 avian influenza diagnosis and surveillance
AU2008254951A1 (en) 2007-05-14 2008-11-27 Biogen Idec Ma Inc. Single-chain Fc (ScFc) regions, binding polypeptides comprising same, and methods related thereto
US7879326B2 (en) 2007-06-15 2011-02-01 The Board Of Trustees Of The Leland Stanford Junior University Human neutralizing monoclonal antibodies to H5N1 influenza A virus
WO2008154813A1 (fr) 2007-06-15 2008-12-24 Xiamen University Anticorps monoclonaux se liant à l'hémagglutinine du virus de la grippe aviaire du sous type h5 et ses utilisations
SG183032A1 (en) 2007-09-13 2012-08-30 Temasek Life Sciences Lab Ltd Monoclonal antibodies specific to hemagglutininand neuraminidase from influenza virus h5-subtypeor n1-subtype and uses thereof
AU2008297586B2 (en) 2007-09-13 2013-06-20 National Institute Of Health Research And Development (Nihrd)- Ministry Of Health Of The Republic Of Indonesia Monoclonal antibodies specific to hemagglutinin from influenza virus H5-subtype and uses thereof
FR2921928B1 (fr) 2007-10-08 2011-03-04 Sanofi Pasteur Anticorps monoclonaux specifiques de l'hemagglutinine du virus grippal
MX2010005229A (es) 2007-11-12 2010-11-05 Univ Pennsylvania Vacunas novedosas contra sub-tipos multiples de virus de influenza.
WO2009073163A1 (en) 2007-12-03 2009-06-11 American Type Culture Collection (Atcc) Avian influenza antibodies, compositions, and methods thereof
AU2008338691B2 (en) 2007-12-06 2015-01-22 Burnham Institute For Medical Research Antibodies against influenza virus and methods of use thereof
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
US7981428B2 (en) 2008-01-23 2011-07-19 Academia Sinica Flu vaccines and methods of use thereof
EP2250197B1 (en) 2008-02-05 2016-05-11 Temasek Life Sciences Laboratory Limited Binding protein and epitope-blocking elisa for the universal detection of h5-subtype influenza viruses
EP2265646B1 (en) 2008-03-12 2016-01-27 Her Majesty, The Queen in Right of Canada, as Represented by The Minister of Health Reagents and methods for detecting influenza virus proteins
ITTO20080204A1 (it) 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
WO2009121004A2 (en) 2008-03-28 2009-10-01 Sea Lane Biotechnologies, Llc Neutralizing molecules to viral antigens
JP5586064B2 (ja) 2008-03-28 2014-09-10 国立大学法人北海道大学 抗ｈ５亜型ａ型インフルエンザウイルスヘマグルチニンモノクローナル抗体
FI20080333A0 (fi) 2008-05-02 2008-05-02 Glykos Finland Oy Influenssaviruksen nukleiinihappoja ja peptidejä
ITTO20080398A1 (it) 2008-05-27 2009-11-28 Pomona Biotechnologies Llc Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1
DK2285408T3 (en) 2008-06-05 2019-02-04 Ablynx Nv AMINO ACID SEQUENCES AGAINST COATING PROTEINS IN A VIRUS AND POLYPEPTIDES INCLUDING THESE FOR TREATMENT OF VIRUSAL DISEASES
BRPI0915487A2 (pt) 2008-07-11 2017-06-27 Medimmune Inc hemaglutina de nfluenza e variantes de neuraminidase
EP2313433A2 (en) 2008-07-25 2011-04-27 Institute for Research in Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
WO2010027818A2 (en) 2008-08-25 2010-03-11 Dana-Farber Cancer Institute, Inc. Conserved hemagglutinin epitope, antibodies to the epitope, and methods of use
US20100061995A1 (en) 2008-09-08 2010-03-11 Damian Michael Carragher Immunotherapy To Treat Or Prevent Viral Infection
GB0818356D0 (en) 2008-10-07 2008-11-12 Istituto Superiore Di Sanito Antibodies
WO2010040281A1 (zh) 2008-10-09 2010-04-15 厦门大学 H5亚型禽流感病毒血凝蛋白的人源化抗体及其用途
JP5837820B2 (ja) 2008-10-22 2015-12-24 インスティテュート・フォー・リサーチ・イン・バイオメディシンＩｎｓｔｉｔｕｔｅ Ｆｏｒ Ｒｅｓｅａｒｃｈ Ｉｎ Ｂｉｏｍｅｄｉｃｉｎｅ 形質細胞から抗体を産生する方法
WO2010074656A1 (en) 2008-12-24 2010-07-01 Temasek Life Sciences Laboratory Limited Monoclonal antibodies specific to the fusion peptide from hemagglutinin from influenza a viruses and uses thereof
CN102264896B (zh) 2008-12-25 2014-02-26 国立大学法人大阪大学 抗人流感病毒人型抗体
US8894997B2 (en) 2009-04-30 2014-11-25 Vanderbilt University Monoclonal antibodies to influenza H1N1 virus uses thereof
CA2761648C (en) 2009-05-11 2019-03-12 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof
EP2430047B1 (en) 2009-05-13 2018-03-28 i2 Pharmaceuticals, Inc. Neutralizing molecules to influenza viruses
IT1395961B1 (it) 2009-06-01 2012-11-02 Pomona Biotechnologies Llc Anticorpi monoclonali come medicamento per il trattamento terapeutico e/o profilattico delle infezioni da virus influenzale a (h1n1) di origine suina (s-oiv)
AU2010266129B2 (en) 2009-07-02 2016-04-14 Massachusetts Institute Of Technology Compositions and methods for diagnosing and/or treating influenza infection
AU2010282415A1 (en) 2009-08-14 2012-03-08 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
EP2483307A1 (en) 2009-09-29 2012-08-08 Fraunhofer USA, Inc. Influenza hemagglutinin antibodies, compositions, and related methods
US9458226B2 (en) 2009-10-09 2016-10-04 Emory University Recombinant antibodies against H1N1 influenza
WO2011068143A1 (ja) 2009-12-03 2011-06-09 独立行政法人科学技術振興機構 Ｈ５亜型インフルエンザウイルスに対する抗体およびその利用
JP2013060367A (ja) 2010-01-15 2013-04-04 Osaka Univ 抗インフルエンザ抗体及びインフルエンザ検出用デバイス
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
JP6210685B2 (ja) 2010-01-27 2017-10-11 マサチューセッツ インスティテュート オブ テクノロジー 標的化された広域スペクトルのインフルエンザ中和のための操作されたポリペプチド剤
JPWO2011093217A1 (ja) 2010-01-29 2013-06-06 富士レビオ株式会社 抗Ｐａｎｄｅｍｉｃ（Ｈ１Ｎ１）２００９抗体及びそれを用いた免疫測定方法
JPWO2011096302A1 (ja) 2010-02-02 2013-06-10 国立大学法人名古屋大学 薬剤耐性インフルエンザウイルス特異的抗体及びその用途
JP2011160681A (ja) 2010-02-05 2011-08-25 Japan Science & Technology Agency Ａ型インフルエンザのヘマグルチニンに対する抗体およびその利用
CA2849668A1 (en) 2010-03-08 2011-09-15 Celltrion, Inc. Human monoclonal antibodies derived from human b cells and having neutralizing activity against influenza a viruses
SI2552485T1 (sl) 2010-03-26 2017-05-31 Pomona Ricerca S.R.L. Imunoglobulini polne dolžine igg izotipa, sposobni prepoznave heteropodtipskega nevtralizacijskega epitopa na hemagglutininskem izvornem področju in njih uporaba kot zdravilo proti gripi
JP6050747B2 (ja) 2010-06-17 2016-12-21 トレリス バイオサイエンス リミテッド ライアビリティー カンパニー インフルエンザ受動免疫化に有用な抗体
AU2011289275A1 (en) 2010-08-12 2013-02-21 Theraclone Sciences, Inc. Anti-hemagglutinin antibody compositions and methods of use thereof
US8992929B2 (en) 2010-08-23 2015-03-31 Temasek Life Sciences Laboratory Limited Monoclonal antibody specific to major neutralizing epitope of influenza H5 hemagglutinin
US9534042B2 (en) 2010-09-03 2017-01-03 Fujita Health University Influenza virus-neutralizing antibody and screening method therefor
WO2012040406A2 (en) 2010-09-21 2012-03-29 Massachusetts Institute Of Technology Influenza treatment and/or characterization; human-adapted ha polypeptides; vaccines
WO2012045001A2 (en) 2010-09-30 2012-04-05 Vanderbilt University Influenza virus antibodies and immunogens and uses therefor
CA2813078A1 (en) 2010-10-04 2012-04-12 Massachusetts Institute Of Technology Hemagglutinin polypeptides, and reagents and methods relating thereto
US8900585B2 (en) 2010-10-20 2014-12-02 New York Blood Center, Inc. Influenza hemagglutinin-specific monoclonal antibodies for preventing and treating influenza virus infection
EP2646050B1 (en) 2010-12-02 2016-09-07 mAB-Factory GmbH Vaccine against influenza h5n1 viruses, medicament and treatment of h5n1 viral infections
US9469685B2 (en) 2011-01-10 2016-10-18 Emory University Antibodies directed against influenza
KR101941724B1 (ko) 2011-07-14 2019-01-23 얀센 백신스 앤드 프리벤션 비.브이. 계통발생군 1과 계통발생군 2의 인플루엔자 a형 바이러스 및 인플루엔자 b형 바이러스를 중화시킬 수 있는 인간 결합분자
HUE044089T2 (hu) 2011-07-18 2019-09-30 Inst Res Biomedicine Neutralizáló anti-influenza A antitestek és alkalmazásaik
EP2739312B1 (en) 2011-08-03 2017-10-04 Children's Medical Center Corporation A broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza hemagglutinin
GB201115214D0 (en) 2011-09-02 2011-10-19 Health Prot Agency Influenza virus antibody compositions
ES2641257T3 (es) 2011-09-30 2017-11-08 Celltrion, Inc. Molécula de unión que tiene actividad neutralizadora contra el virus de la influenza A producida a partir de células B humanas
CN103030693B (zh) 2011-09-30 2015-03-11 中国科学院上海巴斯德研究所 高致病性禽流感的中和分子及其制备方法
EP2768858B1 (en) 2011-10-18 2018-08-01 Emory University Antibodies directed against influenza
KR20130059721A (ko) 2011-11-29 2013-06-07 (주)셀트리온 인간 ｂ 세포에서 생산된 인플루엔자 ａ 바이러스 중화 활성을 가지는 결합 분자
KR20140112495A (ko) 2011-12-02 2014-09-23 에임 쎄라퓨틱스 비.브이. 인플루엔자 a 바이러스 특이적 항체
MX367743B (es) 2011-12-05 2019-09-04 Trellis Bioscience Llc Anticuerpos utiles para la inmunizacion pasiva de influenza.
KR101749316B1 (ko) 2011-12-15 2017-06-21 (주) 에이프로젠 Ｈ１ｎ１―감염된 환자들로부터 유도된 매우 잠재력 있는 넓은-스펙트럼 중화 단일클론 항체 및 이를 포함하는 바이러스의 치료용 조성물
WO2013114885A1 (en) 2012-01-31 2013-08-08 Osaka University Human monoclonal antibodies broadly protective against influenza b virus and methods of using the same
MY170407A (en) 2012-03-08 2019-07-27 Crucell Holland Bv Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
CA2871160C (en) 2012-05-10 2023-03-14 Massachusetts Institute Of Technology Agents for influenza neutralization
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
CN105263954B (zh) 2013-02-07 2019-12-03 麻省理工学院 H5流感的人类适应
SMT202000505T1 (it) 2013-10-02 2020-11-10 Medimmune Llc Anticorpi anti-influenza a neutralizzanti e relativi usi
RU2682049C2 (ru) 2014-01-27 2019-03-14 Дженентек, Инк. Лечение вируса гриппа а h7n9
TWI701258B (zh) 2014-12-19 2020-08-11 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
EP3280730B1 (en) 2015-04-08 2024-01-03 Dana-Farber Cancer Institute, Inc. Humanized influenza monoclonal antibodies and methods of use thereof
EP3374390A1 (en) 2015-11-13 2018-09-19 Visterra, Inc. Compositions and methods for treating and preventing influenza
PE20181516A1 (es) 2015-12-15 2018-09-21 Shionogi & Co Medicamento para tratar la gripe caracterizado por combinar un inhibidor de endonucleasa dependiente de cap y un farmaco antigripal
JP7104629B2 (ja) 2016-02-24 2022-07-21 ビステラ， インコーポレイテッド インフルエンザウイルスに対する抗体分子の製剤
AU2020248404A1 (en) * 2019-03-25 2021-09-30 Visterra, Inc. Compositions and methods for treating and preventing influenza
KR20220113749A (ko) 2019-12-11 2022-08-16 비스테라, 인크. 인플루엔자를 치료하고 예방하는 조성물 및 방법

Also Published As

Publication number Publication date
US20130302349A1 (en) 2013-11-14
US20220204592A1 (en) 2022-06-30
HK1208619A1 (en) 2016-03-11
AU2013259371A1 (en) 2014-10-30
JP6363066B2 (ja) 2018-07-25
IL235585B (en) 2020-10-29
BR112014028109A2 (pt) 2017-06-27
US20140148581A1 (en) 2014-05-29
SG11201407265RA (en) 2014-12-30
JP2015519052A (ja) 2015-07-09
US9096657B2 (en) 2015-08-04
WO2013170139A1 (en) 2013-11-14
JP2018015012A (ja) 2018-02-01
KR102194936B1 (ko) 2020-12-28
CN104602709A (zh) 2015-05-06
CN108948189A (zh) 2018-12-07
CL2014003051A1 (es) 2015-07-10
CA2872308A1 (en) 2013-11-14
US12024552B2 (en) 2024-07-02
SG10201605669WA (en) 2016-08-30
EP2846832B1 (en) 2020-01-22
AU2013259371B2 (en) 2018-01-04
EP2846832A1 (en) 2015-03-18
KR102366115B1 (ko) 2022-02-23
JP6800828B2 (ja) 2020-12-16
ES2785306T3 (es) 2020-10-06
KR20150008164A (ko) 2015-01-21
US20150037352A1 (en) 2015-02-05
US9969794B2 (en) 2018-05-15
CN104602709B (zh) 2018-07-31
IL235585A0 (en) 2015-01-29
CA2872308C (en) 2021-01-26
MX2014013668A (es) 2015-04-08
US8877200B2 (en) 2014-11-04
MX2019007921A (es) 2019-09-10
US10800835B2 (en) 2020-10-13
AU2018200451A1 (en) 2018-02-08
EP3689377A1 (en) 2020-08-05
US20190002536A1 (en) 2019-01-03
KR20200142127A (ko) 2020-12-21
AU2018200451B2 (en) 2019-01-03
AU2019202107A1 (en) 2019-05-02

Similar Documents

Publication Publication Date Title
MX366180B (es) Nuevos agentes de union a ha.
CL2017001610A1 (es) Anticuerpos humanos para hemagglutinina de influenza
CY1121862T1 (el) Αντισωματα anti-phf-tau και χρησεις αυτων
BR112016022113A2 (pt) anticorpos anti-hemaglutinina do vírus influenza b e métodos de uso
EA201891339A1 (ru) Водный фармацевтический препарат, который содержит антитело к pd-l1 авелумаб
MX2021004687A (es) Anticuerpo anti-influenza a neutralizantes y usos de los mismos.
EA201591164A1 (ru) Вакцины против вируса гриппа и их применение
CU24533B1 (es) Anticuerpos o fragmentos de los mismos que se unen a linfopoyetina estromal tímica (tslp) y composiciones farmacéuticas de los mismos
CL2016000460A1 (es) Proteínas de unión al antígeno gitr
UY36889A (es) Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
EA201490659A1 (ru) Вакцины против вируса гриппа и их применения
BR112016022658A2 (pt) anticorpos anti-ox40 e métodos de uso
CR20140382A (es) Anticuerpos anti-lrp5 y metodos de uso
BR112017011234A2 (pt) anticorpos contra receptor da barreira hematoencefálica e métodos de uso
CR20150618A (es) Anticuerpos receptores de antitransferina y métodos de uso
BR112017011932A2 (pt) ?anticorpos direcionados a receptor acoplado a proteína g e métodos de uso?
BR112015032224A2 (pt) anticorpos anti-fcrh5
BR112014033116A2 (pt) anticorpos para tau
BR112015021521A2 (pt) anticorpos anti-crth2 e métodos para seu uso
BR112017012954A2 (pt) composições e métodos para anticorpos que têm como alvo a bmp6
MX2015012872A (es) Anticuerpos anti-tau y metodos de uso.
CR20140212A (es) Anticuerpos anti-htra1 y métodos de uso
ECSP14028523A (es) Moléculas de anticuerpo anti-gcc y uso de las mismas
CR20150247A (es) Anticuerpos de antihemaglutinina y métodos de uso
MX392761B (es) Anticuerpos anti-influenza b neutralizantes y usos de los mismos.

Legal Events

Date Code Title Description
FG Grant or registration